4-1BBL is a member of the tumor necrosis factor (TNF) receptor family. This receptor contributes to the clonal expansion, survival, and development of T cells. In addition, 4-1BBL expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. CD137 has been shown to interact with TRAF2. The human 4-1BBL gene codes for a 254 amino acid type II transmembrane containing a 28 amino acid cytoplasmic domain, a 21 amino acid transmembrane domain, and a 205 amino acid extracellular domain (ECD). The human 41BBL ECD shares 32 % and 35 % a.a. identity with murine and rat ECD.
Source
Escherichia coli.
Molecular Weight
Approximately 19.4 kDa, a single non-glycosylated polypeptide chain containing 184 amino acids.
Biological Activity
Fully biologically active when compared to standard. The ED50 as determined by stimulation of IL-8 production using human PBMC is less than 10 ng/ml, corresponding to a specific activity of > 1.0 × 105 IU/mg.
Appearance
Sterile filtered white lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.4.
Endotoxin
Less than 1 EU/ug of rHu4-1BBL as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution.
